NanoViricides flu candidate shows promise. Par Pharma jumps on strong earnings Print E-mail
By BioMedReports.com Staff   
Wednesday, 03 November 2010 18:48

Below is a look at some of the headlines for companies that made news in the healthcare sector on November 3, 2010.


NanoViricides, Inc. (OTC BB: NNVC.OB) reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu® treated animals.

Animals treated with the best of the optimized FluCide nanoviricide drug candidates survived greater than twice as long (18.1 days) as opposed to the animals treated with Tamiflu (only 7.8 days). In a previous study, the Company had reported that animals treated with the then best anti-influenza nanoviricides survived for as long as 13.9 days in the same animal model.

On volume of more than 2 million shares, the stock rose more than 23% or 25 cents to $1.31.

Shares of Par Pharmaceutical Companies, Inc. (NYSE:PRX) jumped more than 12% today after the company reported Q3 earnings that were far ahead of Wall Street's estimates. Par attributed the performance to strong sales of its generic version of Prilosec, Omerprazole sodium bicarbonate capsules, which was launced in June.

Shares of Par closed the day at $37.05, up $3.97. The stock has risen more than 25% over the last quarter.

Shares of Uroplasty Inc. (Nasdaq:UPI) surged more than 18% today after the company announced that the Centers for Medicare and Medicaid Services (CMS) has published, in the November, 2010 Federal Register, the anticipated Category I CPT code for Posterior Tibial Nerve Stimulation (PTNS). Uroplasty's Urgent® PC Neuromodulation System is used to provide PTNS and effective January 1, 2011, this procedure will now be billed under the new CPT code 64566, with the descriptor "Posterior tibial neurostimulation, percutaneous needle electrode, single treatment, includes programming."

CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, announced that the Centers for Medicare and Medicaid Services ("CMS") has established a national rate in The Medicare Program Final Rule for the technical component of mobile cardiovascular telemetry (CPT Code 93229). Based on the information currently available, we expect a price of approximately $800 for our geographical area to become effective on January 1, 2011, which will replace the carrier price of $754 previously implemented by Highmark Medicare Services.

AVI BioPharma, Inc. (NASDAQ:AVII), a developer of RNA-based therapeutics, announced today that it has been awarded five cash grants totaling approximately $1.2 million under the U.S. Government's Qualifying Therapeutic Discovery Project (QDTP) program. AVI was awarded grants for each of the five project applications submitted for the company's Duchenne muscular dystrophy program and four infectious disease programs.

Omeros Corporation (Nasdaq:OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has been awarded non-taxable grants totaling approximately $1.7 million under the Qualifying Therapeutic Discovery Project (QTDP) included in the Patient Protection and Affordable Health Care Act of 2010.

OPKO Health, Inc. (NYSE Amex: OPK) announced that it has made an investment in Fabrus, LLC, a privately held early stage biotechnology company with next generation therapeutic antibody drug discovery and development capabilities. In exchange for the Company’s investment, the Company acquired approximately 13% of Fabrus’ outstanding membership interests on a fully diluted basis.

"Fabrus is using its proprietary antibody screening and engineering approach to discover promising lead compounds against several important oncology targets," said Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer. "We believe the Fabrus discovery approach is novel, rapid, provides valuable data at very early discovery stages, and can screen multiple targets or pathways in parallel. We are pleased to secure a stake in this cutting edge company, and we look forward to rapidly developing important drug candidates."

Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) today announced that the commercial launch is now underway for H.P. Acthar® Gel (repository corticotropin injection) as monotherapy for the treatment of Infantile Spasms (IS) in infants and children under the age of two years. This new Acthar indication was approved by the U.S. Food and Drug Administration (FDA) on October 15, 2010.

Acthar provides an important treatment option for children suffering from IS, an ultra-rare form of childhood epilepsy that afflicts an estimated 2,000 children in the U.S. annually. While Acthar has been used by many child neurologists in the treatment of IS for more than 50 years, approval of the IS indication allows Questcor for the first time to engage in direct proactive dialogue with these physicians about Acthar dosing guidelines, adverse events and potential treatment benefits.

Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that it has been awarded grants totaling $977,900 under the Qualifying Therapeutic Discovery Project (QTDP) Program administered under section 48D of the Internal Revenue Code.

Also Wednesday:

 

AdCare Health Systems, Inc. (NYSE Amex:ADK), a recognized innovator in senior living and health care facility management, has secured a $5 million revolving line of credit from Gemino Healthcare Finance, LLC, a specialty healthcare lender that provides senior debt financing to healthcare service providers.

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board:ADLS)
, a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has been awarded a cash grant under the Qualifying Therapeutic Discovery Project which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

Aethlon Medical, Inc. (OTC Bulletin Board:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it will present tomorrow at the at the Singular Research Fifth Annual "Best of the Uncovereds" Conference in Los Angeles.

AmbiCom Holdings, Inc. (OTCBB: ABHI), a leader in the development of wireless products formedical equipment suppliers, today announced that it has received a new $1.2 million purchase order from a major client for AmbiCom's Wi-Fi solution to be used in infusion pumps for North American customers.

The Board of Directors of Atrion Corporation (NASDAQ:ATRI) today announced its quarterly cash dividend of 42 cents per share on its outstanding shares of Common Stock.

Callidus Software Inc. (NASDAQ:CALD), the leader in Sales Performance Management (SPM), announced today that Blue Cross of Northeastern Pennsylvania, an independent licensee of the Blue Cross and Blue Shield Association, has selected ActekSoft, a Callidus Software company, for its ACom3 Commission and Incentive Compensation System.

Caliper Life Sciences, Inc. (Nasdaq:CALP), a leading provider of tools and services for drug discovery and life sciences research, today announced a collaboration with Sony DADC Austria AG for the co-development and manufacture of plastic consumables for Caliper's next generation microfluidics products.

Cambrex Corporation (NYSE:CBM)
reports third quarter results for the period ended September 30, 2010.

Cardium Therapeutics (NYSE AMEX:CXM) today announced that it was awarded a cash grant of approximately $245,000 under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program to further its Generx clinical development program.

CTI (OTC Bulletin Board: CVAT, Berlin & Stuttgart: WTC) proudly announces that its common shares are now also listed on the Frankfurt Stock Exchange under the ticket symbol WTC.

Cypress Bioscience, Inc. (NASDAQ:CYPB)
today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present atOppenheimer's 21st Annual Healthcare Conference today, November 3, 2010.

Dendreon Corporation (Nasdaq:DNDN) today reported results for the quarter ended September 30, 2010. Revenue for the third quarter ended September 30, 2010 was $20.2 million compared to $25,000 for the quarter ended September 30, 2009.

D-Pharm (TASE: DPRM) announced today the appointment of Hangzhou Tigermed Consulting Co., Ltd as the contract research organization to manage the regulatory filings and conduct the clinical trials of DP-b99, in China.

First China Pharmaceutical Group, Inc. (OTCBB:FCPG) wishes to advise that after a period of 5 months of informal talks, the Company is pleased to announce the signing of a Letter of Intent ("LOI") outlining plans for the acquisition of 100% of the interests of De Xin Pharmacy ("De Xin") located in Kunming City (pop. 5,740,000), the capital of Yunnan Province, China.

GeckoSystems Intl. Corp. (PINKSHEETS: GOSY) announced today that their CEO, Martin Spencer, will be meeting with senior Japanese government officials per their request in early December to discuss the societal impacts of life support personal companion robots, such as GeckoSystems' CareBot(tm).

Given Imaging Ltd. (NASDAQ: GIVN) today announced financial results for the third quarter ended September 30, 2010.

Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible medical robotics and the developer of robotic technology for accurate 3D control of catheter movement, today reported its recent business highlights and financial results for the third quarter ended September 30, 2010.

Impact Fusion International, Inc. (PINKSHEETS:IFUS) The Company announced today Dr. Bear Walker has agreed to be the Chairman of the Company's Medical Advisory Board.

Martek Biosciences Corporation (Nasdaq:MATK) announced today that it will be presenting at the 2010 Citi Small / Mid Cap Conference being held on November 16-17, 2010 in Las Vegas, NV.

Medical Marijuana Inc (PINKSHEETS:MJNA) continues to execute their business plan with The Hemp Network building every day.

Ohr Pharmaceutical Inc. (OTCBB: OHR), a developer of therapeutics for cancer cachexia, wet age-related macular degeneration, and oncology applications, announced today that it has been awarded $244,000 under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010.

ProPhase Labs (NASDAQ: PRPH) announced today that financial results for the third quarter, ended September 30, 2010, will be released before market open on Wednesday, November 10, 2010.

Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today plans to participate in nine key industry events throughout fiscal year 2011 as part of the Company's continueddedication to the oncology and in vitro diagnostics (IVD) sectors.

Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board:SNGX), a late-stage biopharmaceutical company, announced today that the Company has been awarded a cash grant totaling $244,479 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program.

Somatic Systems, Inc. (PINKSHEETS: SMAS) is pleased to be opening its second location for its Somatics Professional Training Program.

Spherix Incorporated (Nasdaq:SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its subsidiary, Biospherics Incorporated, has been awarded $469,479 under HR: 3590 – Patient Protection and Affordable Care Act (the "Act") in immediately available funds.

Telik, Inc. (Nasdaq:TELK) today reported a net loss of $4.7 million, or $0.09 per share, for the third quarter ended September 30, 2010, compared with a net loss of $6.1 million, or $0.11 per share, for the comparable period in 2009.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter